Raymond James lowered the firm’s price target on Bausch Health (BHC) to $8 from $9 and keeps a Market Perform rating on the shares. Bausch Health reported a “solid” Q1 overall, with adjusted EBITDA and revenue strength across all businesses except Bausch + Lomb (BLCO) and International, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
- Bausch Health Earnings Call Highlights Growth and Challenges
- Cautious Outlook on Bausch Health: Sell Rating Amid Strategic Uncertainty and Tariff Concerns
- Bausch Health Reports Q1 2025 Financial Results
- Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing